Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2022 | Cardiovascular disease risk in patients with breast cancer

Ilana Schlam • 7 Dec 2022
SABCS 2022
Breast Cancer Antibodies Trastuzumab

Ilana Schlam, MD, Tufts Medical Center, Boston, MA, discusses guidelines to cardiovascular surveillance and the significance of personalizing treatment to help prevent cardiovascular disease in patients with breast cancer. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Ilana Schlam

0:57
Cardiovascular risk evaluation for breast cancer survivors: A pilot study
Ilana Schlam • 7 Dec 2022
0:37
Challenges HPCs face when monitoring for cardiotoxicity in patients with breast cancer
Ilana Schlam • 7 Dec 2022
0:55
Results from a pilot study exploring cardiovascular risk evaluation for breast cancer survivors
Ilana Schlam • 7 Dec 2022
0:41
Improving cardiovascular health for patients with breast cancer
Ilana Schlam • 7 Dec 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals